


Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
by OmniSeq Staff | Jan 24, 2019

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
by Christina Black | May 9, 2018
...Follow Us on Twitter
LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine
Last year, the Buffalo-based cancer diagnostics firm @OmniSeq quietly was acquired by one of the world's largest life science companies, @Labcorp . Developing molecular diagnostic tests for cancer patients, OmniSeq is looking to scale its operations.
https://tinyurl.com/muxryphz